Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study-Reference-Cited by-同舟云学术

Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study

Published:2024-01-11 Issue:1 Volume:29 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Zhan Linquan¹,Yuan Dai¹²,Ge Xueling²,Ding Mei²,Wang Jianhong²,Zhou Xiangxiang²³,Wang Xin¹²⁴³

Affiliation:

1. Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, People’s Republic of China

2. Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People’s Republic of China

3. National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China

4. Branch of National Clinical Research Center for Hematologic Diseases, Jinan, People’s Republic of China

Funder

National Natural Science Foundation

Key Research and Development Program of Shandong Province

China Postdoctoral Science Foundation

NCRCH

Shandong Provincial Natural Science Foundation

Taishan Scholars Program of Shandong Province

Shandong Provincial Engineering Research Center of Lymphoma

Academic Promotion Programme of Shandong First Medical University

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2023.2293579

Reference46 articles.

1. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN);Palumbo A;Blood,2011

2. Multiple myeloma;Palumbo A;N Engl J Med,2011

3. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

4. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): multiple myeloma. Version 4.2023. 2023.